ProQR Therapeutics N.V. (PRQR) Bundle
A Brief History of ProQR Therapeutics N.V. (PRQR)
Foundation and Early Development
ProQR Therapeutics N.V. was founded in 2012 in Leiden, Netherlands. The company focused on developing transformative RNA medicines for genetic diseases. Its mission centered on treating rare genetic disorders by leveraging its innovative RNA editing and delivery technology.
Key Product Developments
The company’s lead product candidate, QR-110, is aimed at treating Leber Congenital Amaurosis (LCA), a rare genetic disorder affecting vision. In November 2019, ProQR reported positive results from its Phase 1/2 clinical trial.
| Year | Milestone | Trial Phase | Results |
|---|---|---|---|
| 2019 | Initial Phase 1/2 trial results for QR-110 | Phase 1/2 | Positive |
| 2021 | Initiation of Phase 2 trial for QR-110 | Phase 2 | Underway |
| 2023 | Announced new data for QR-110 | Ongoing | Promising |
Financial Growth and Market Performance
ProQR Therapeutics went public on the NASDAQ under the ticker symbol PRQR in 2014. The initial public offering (IPO) priced at $12 per share raised approximately $66 million.
As of Q2 2023, the company reported a cash position of approximately $67 million, which is expected to fund operations into 2025.
| Fiscal Year | Revenue (in millions) | Net Loss (in millions) | R&D Expenses (in millions) |
|---|---|---|---|
| 2020 | 0.8 | (10.5) | 8.3 |
| 2021 | 1.2 | (15.1) | 12.5 |
| 2022 | 1.5 | (18.9) | 15.7 |
| 2023 (Q2) | 0.5 | (5.2) | 2.9 |
Strategic Collaborations and Partnerships
ProQR has engaged in multiple collaborations to enhance its drug development pipeline:
- Partnership with University of Pennsylvania to develop RNA medicines for various genetic disorders.
- Collaboration with AbbVie for the development of RNA therapies.
Recent Achievements and Future Directions
As of 2023, ProQR has expanded its pipeline with several candidates in various stages of clinical development, including:
- QR-421a for Usher syndrome type 2A, currently in Phase 1/2 trials.
- QR-1123 for Fuchs endothelial corneal dystrophy, in Phase 1 trials.
In March 2023, ProQR announced a collaboration with Vifor Pharma to develop its RNA therapies, expanding its reach into novel therapeutic areas.
Market Impact and Stock Performance
ProQR’s stock price has experienced volatility, notably reaching a high of approximately $28 in mid-2019 and a low around $3 in 2022. As of October 2023, the stock trades near $5.50, reflecting ongoing investor interest in its innovative approaches.
A Who Owns ProQR Therapeutics N.V. (PRQR)
Company Overview
Company Overview
ProQR Therapeutics N.V. (NASDAQ: PRQR) is a biotechnology company dedicated to transforming the lives of patients with genetic diseases through the development of RNA-based therapies. As of October 2023, the company focuses primarily on conditions like cystic fibrosis and Usher syndrome.
Major Shareholders
As of the latest available filings, the ownership structure of ProQR Therapeutics includes various institutional investors, individual shareholders, and company executives.
| Shareholder Type | Name | Ownership Percentage | Number of Shares |
|---|---|---|---|
| Institutional Investor | BlackRock, Inc. | 7.10% | 1,652,309 |
| Institutional Investor | The Vanguard Group, Inc. | 6.50% | 1,525,000 |
| Institutional Investor | FMR LLC (Fidelity) | 5.80% | 1,400,000 |
| Individual Investor | Daniel de Boer (CEO) | 1.50% | 350,000 |
| Individual Investor | Johan van der Waart (CFO) | 1.20% | 280,000 |
| Institutional Investor | Sabby Management LLC | 4.00% | 940,000 |
Market Capitalization
As of October 2023, ProQR Therapeutics had a market capitalization of approximately $180 million.
Recent Stock Performance
The stock performance of PRQR over the last year has reflected volatility typical in the biotech sector. The following data summarizes key financial metrics:
| Date | Stock Price ($) | Market Cap ($ million) | Volume |
|---|---|---|---|
| October 2023 | 3.80 | 180 | 450,000 |
| July 2023 | 4.20 | 200 | 600,000 |
| April 2023 | 5.00 | 210 | 500,000 |
| January 2023 | 2.90 | 140 | 300,000 |
Leadership Team Ownership
The leadership team holds a significant amount of shares, contributing to their vested interest in the company’s success. The following table outlines their ownership:
| Name | Position | Shares Owned | Percentage of Total Shares |
|---|---|---|---|
| Daniel de Boer | CEO | 350,000 | 1.50% |
| Johan van der Waart | CFO | 280,000 | 1.20% |
| Elin H. M. Jansen | Chief Medical Officer | 150,000 | 0.60% |
Recent Developments
ProQR has made strides in clinical trials, garnering attention from investors. Their pipeline includes several promising therapies currently under investigation.
Conclusion
The ownership structure and major stakeholders in ProQR Therapeutics indicate a robust involvement from institutional investors, while the company leadership maintains a significant stake, aligning their interests with those of shareholders.
ProQR Therapeutics N.V. (PRQR) Mission Statement
Corporate Overview
ProQR Therapeutics N.V., founded in 2012, is a biotechnology company focused on developing transformative RNA therapies for severe genetic diseases. The company's mission is to leverage its proprietary RNA editing technology to create life-changing treatments for patients who currently have no options.
Mission Statement
ProQR's mission is to improve the lives of patients through innovative RNA medicines. By focusing on genetic diseases with high unmet medical need, ProQR endeavors to make a meaningful difference in the lives of patients.
Key Objectives
- Development of RNA therapies that target the root cause of genetic disorders.
- Expansion of clinical pipelines to include both rare and common diseases.
- Collaboration with leading institutions for research and development.
- Commitment to sustainability and ethical practices in drug development.
Financial Overview
As of October 2023, ProQR Therapeutics reported the following financial metrics:
| Metric | Value |
|---|---|
| Total Revenue (2022) | $20.1 million |
| Net Loss (Q2 2023) | -$5.3 million |
| Cash and Cash Equivalents (Q2 2023) | $67.9 million |
| Market Capitalization (October 2023) | $225 million |
Research and Development Focus
ProQR has a robust pipeline focusing on the following areas:
- Leber Congenital Amaurosis (LCA)
- Usher Syndrome
- Cystic Fibrosis
- Other rare genetic disorders
Strategic Partnerships
The company has engaged in several collaborations to enhance its research capabilities:
| Partner | Type of Collaboration |
|---|---|
| University of California, San Diego | Research collaboration for RNA therapies |
| University of Florida | Partnership on genetic disease research |
| Foundation for the National Institutes of Health | Partnership to advance genetic research |
Impact on Patients
ProQR aims to provide options for patients suffering from genetic diseases through the following:
- Innovative therapies that directly target genetic mutations.
- Patient-centric approach in drug development.
- Engagement with patient communities for feedback and insights.
Future Goals
ProQR's future goals include:
- Advancing clinical trials for their lead candidates.
- Expanding their pipeline into additional genetic disorders.
- Increasing global outreach to ensure access to their therapies.
How ProQR Therapeutics N.V. (PRQR) Works
Company Overview
ProQR Therapeutics N.V., founded in 2014, specializes in developing RNA-based therapies for severe genetic diseases. The company is headquartered in Leiden, the Netherlands, and is publicly traded on the NASDAQ under the ticker symbol PRQR.
Financials
As of the latest fiscal year-end in 2022:
- Annual Revenue: $0.5 million
- Net Loss: $49.2 million
- Total Assets: $72.3 million
- Cash and Cash Equivalents: $54.1 million
- Market Capitalization: Approximately $215 million (as of October 2023)
Research and Development
ProQR invests significantly in R&D, with expenses amounting to $38.6 million in 2022, representing about 78% of total operating expenses for that year. The company focuses on developing treatments for ophthalmic diseases, cystic fibrosis, and neurodegenerative disorders.
Pipeline Products
ProQR's pipeline includes several RNA therapies:
- Amenable to Targeting Cystic Fibrosis: QR-010
- Usher Syndrome Type 2A: QR-421a
- Leber Congenital Amaurosis: QR-1123
- Other indications include various genetic disorders under early clinical trials.
| Product | Indication | Development Stage | Expected Milestones |
|---|---|---|---|
| QR-010 | Cystic Fibrosis | Phase 1/2 | Phase 2 results Q4 2023 |
| QR-421a | Usher Syndrome | Phase 1/2 | Data readout H2 2024 |
| QR-1123 | Leber Congenital Amaurosis | Preclinical | IND submission by 2025 |
Collaborations and Partnerships
ProQR engages in strategic collaborations to enhance its research capabilities:
- Partnership with Moderna for mRNA technology applications.
- Collaboration with the University of Leiden on genetic disorders.
- Agreement with the Cystic Fibrosis Foundation for joint research initiatives.
Market Outlook
The global gene therapy market is projected to reach approximately $9.3 billion by 2029, growing at a CAGR of 33.3% from 2023. ProQR aims to capture a portion of this market with its innovative therapies.
Management Team
Key members of the management team include:
- Daniel A. de Boer - CEO and co-founder
- Miriam M. S. M. D. de Boeck - Chief Medical Officer
- Johan van der Velden - Chief Financial Officer
As of October 2023, ProQR continues to advance in clinical trials and expand its influence in the biotechnology sector through strategic partnerships and significant investment in research and development.
How ProQR Therapeutics N.V. (PRQR) Makes Money
Revenue Streams
ProQR Therapeutics N.V. primarily generates revenue through the development and commercialization of innovative RNA-based therapies. Their business model includes:
- Collaborative partnerships
- License agreements
- Grants and funding
Collaborative Partnerships
ProQR engages in partnerships with pharmaceutical companies and research institutions to develop its drug candidates. In 2021, ProQR entered into a collaboration with AbbVie Inc. for the development of RNA-based therapies for ophthalmic diseases, valued at approximately $45 million in upfront payments and potential milestones.
License Agreements
The company also generates revenue through license agreements. In 2020, ProQR signed a licensing agreement with Regeneron Pharmaceuticals, providing them with exclusive rights to develop and commercialize selected ProQR compounds, leading to an initial payment of $10 million and potential future payments up to $200 million.
Grants and Funding
ProQR benefits from public and private funding opportunities to support its research initiatives. In 2021, the company received a grant of $1.8 million from the Netherlands' Innovative Medicines Initiative for the development of its lead candidate, QR-421a.
Financial Performance
For the year ended December 31, 2022, ProQR reported total revenue of $5.1 million, primarily derived from collaborations and research funding. The revenue breakdown was as follows:
| Source | Amount (in millions) |
|---|---|
| Collaborative Revenue | $3.3 |
| License Fees | $1.5 |
| Grants | $0.3 |
Research and Development (R&D) Expenses
In 2022, ProQR invested significantly in R&D, spending approximately $31.6 million, which constituted around 90% of their total operating expenses. The key areas of focus included:
- Clinical trials for QR-421a
- Preclinical development of pipeline candidates
- Expansion of RNA-editing technologies
Market Capitalization
As of October 2023, ProQR Therapeutics N.V. had a market capitalization of approximately $200 million. The stock price has fluctuated significantly, with a 52-week range of $2.00 to $9.00 per share.
Recent Developments
In September 2023, ProQR announced positive interim data from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome type 2A, which has the potential to impact revenue positively. Estimated peak sales for this indication are projected at around $1 billion by 2030.
Conclusion
ProQR Therapeutics' financial strategy, focused on innovative therapies, collaborations, and securing funding, positions the company for growth in the biotech sector. The financial outlook remains contingent on successful clinical trial outcomes and commercial partnerships.
ProQR Therapeutics N.V. (PRQR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support